Larazotide
Also known as: AT-1001, INN-202, Larazotide acetate
Source Larazotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Larazotide acetate (AT‑1001) is an orally administered synthetic octapeptide that antagonizes zonulin signaling, investigated for treatment of celiac disease and other disorders of intestinal barrier dysfunction.
Mechanism of Action
Blocks zonulin receptor to tighten intestinal tight junctions and reduce paracellular permeability
Routes of Administration
Goals & Uses
- Adjunct to gluten-free diet in celiac diseaseDisease ManagementModerate
- Reduce gastrointestinal symptoms in celiac diseaseSymptom ManagementModerate
- Non‑celiac gluten sensitivityGastrointestinalLow
- Treatment of type 1 diabetes (experimental)Autoimmune DiseaseLow
- Attenuation of gluten-induced immune activationImmunomodulationLow
- Reduce intestinal permeability in celiac diseaseGastrointestinal Barrier FunctionModerate
- Celiac diseaseAutoimmune GastrointestinalModerate
Contraindications
- Known hypersensitivity to larazotide or any excipientAllergyHigh
- Known hypersensitivity to larazotide or any excipientsAllergyModerate
Adverse Effects
- HeadacheNeurologicCommonPain in the head or upper neck
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Upper respiratory tract infectionInfectiousUncommon
- DiarrheaGastrointestinalUncommonLoose or frequent stools
- Abdominal painGastrointestinalCommonPain or discomfort in the abdomen
Drug Interactions
- None reportedLow
- Gluten-containing medicationsModerate
Population Constraints
- Pediatric patientsAgeRelative
- Children < 12 yearsPediatricRelative
- Patients with severe renal or hepatic impairmentOrgan ImpairmentRelative
- Pregnant or breastfeeding womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalUnder clinical investigation
- United StatesInvestigationalPhase III trials for celiac disease
- United KingdomInvestigationalSame as EU
Completed Phase II trials; Phase III ongoing as of 2024; not approved in any jurisdiction.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Larazotide?
Larazotide acetate (AT‑1001) is an orally administered synthetic octapeptide that antagonizes zonulin signaling, investigated for treatment of celiac disease and other disorders of intestinal barrier dysfunction.
What is Larazotide used for?
Larazotide is educationally associated with: Adjunct to gluten-free diet in celiac disease, Reduce gastrointestinal symptoms in celiac disease, Non‑celiac gluten sensitivity, Treatment of type 1 diabetes (experimental), Attenuation of gluten-induced immune activation, Reduce intestinal permeability in celiac disease, Celiac disease. Educational only — not medical advice.
How is Larazotide administered?
Recorded routes of administration: Oral.
What are the potential side effects of Larazotide?
Reported adverse effects include: Headache, Nausea, Upper respiratory tract infection, Diarrhea, Abdominal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Larazotide?
Recorded contraindications: Known hypersensitivity to larazotide or any excipient, Known hypersensitivity to larazotide or any excipients. Consult a qualified clinician before use.